Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Vehicle) Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging

NCT04586816
View directory record Official record
Conditions
Photoaging, Hyperpigmentation, Rhytides
Interventions
1% red maple leaf extract in cream base, 5% red maple leaf extract, vehicle
Combination Product
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
30 Years to 70 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 5, 2026, 10:09 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

NCT05361733
View directory record Official record
Conditions
Focus of the Study: Safety of XFB19
Interventions
XFB19, Placebo
Drug
Lead sponsor
Xfibra, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 5, 2026, 10:09 AM EDT
Recruiting Phase 3 Interventional

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

NCT07140783
View directory record Official record
Conditions
Vision Loss Night, Vision Disorders
Interventions
0.75% Phentolamine Ophthalmic Solution, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 5, 2026, 10:09 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT04885972
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
Interventions
Resiniferatoxin, Zilretta, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
La Mesa, California • Pasadena, California • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT04913519
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 4 Interventional

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

NCT03900026
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

NCT00616993
View directory record Official record
Conditions
Inflammation
Interventions
Difluprednate, Placebo
Drug · Other
Lead sponsor
Sirion Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2011 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

Topical Antifungal Treatment for Tinea Pedis

NCT01396785
View directory record Official record
Conditions
Tinea Pedis
Interventions
33525, Placebo
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Paramus, New Jersey • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

NCT01579084
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
AGN-199201 Formulation A, AGN-199201 Formulation B, AGN-199201 Formulation C, AGN-199201 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838
View directory record Official record
Conditions
Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

NCT02933866
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
DSXS topical, Vehicle topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NCT05799157
View directory record Official record
Conditions
Verruca Vulgaris, Warts, Common Wart
Interventions
VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
9 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

NCT02492321
View directory record Official record
Conditions
Allergic Conjunctivitis (AC)
Interventions
EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
11
States / cities
Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

NCT01084824
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
Liquid nitrogen and cantharidin, Liquid nitrogen and topical placebo
Drug
Lead sponsor
North Idaho Dermatology
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

NCT00739349
View directory record Official record
Conditions
Dry Eye
Interventions
NOVA22007 ''Cyclosporine'', vehicle/placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lewiston, Maine
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

NCT05154955
View directory record Official record
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Encino, California • San Diego, California • Rolling Meadows, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

NCT01369589
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
P-552, Placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

NCT00130364
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 11 Years
Enrollment
200 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Novartis Pharmaceuticals, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

NCT00539929
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Hot Springs, Arkansas • San Diego, California • Boise, Idaho + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 5, 2026, 10:09 AM EDT